Genocea names Katrine Bosley as new chairman; GSK, Theravance lung therapy wins OK for asthma, COPD;

@FierceBiotech: Tufts: Big Pharma bets its future on a swelling pipeline of biologic. Article | Follow @FierceBiotech

@JohnCFierce: A More | Follow @JohnCFierce

@DamianFierce: FierceBiotech, coming soon to an Android near you. (Get your iPhone/iPad version in the iTunes store.) Download | Follow @DamianFierce

@EmilyMFierce: Federal government to transfer laboratory chimps to sanctuaries. Story | Follow @EmilyMFierce

> Cambridge, MA-based Genocea Biosciences named Katrine Bosley, the former CEO of Avila, as its new chairman of the board. Release (PDF)

> Relvar, a new lung drug from GlaxoSmithKline ($GSK) and Theravance ($THRX) , has been approved in Europe to treat asthma and COPD. Story

> Isis Pharmaceuticals ($ISIS) earned a $5 million milestone following GlaxoSmithKline's ($GSK) designation of ISIS-GSK4Rx as a development candidate to treat an undisclosed ocular disease. Release

Medical Device News

@FierceMedDev: TriVascular lands $40M round for aortic stent grafts. Story | Follow @FierceMedDev

@MarkHFierce: Medtronic's latest earnings report comes out on Nov. 19. | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Brain tumors succumb to drugs delivered via bone scaffold. More | Follow @MichaelGFierce

> Medtronic guidewires draw Class I recall due to deadly risk. Article

> CareFusion scoops up GE Healthcare Vital Signs arm for $500M. News

> Varian Medical eyes repurchase of 6 million more shares through 2014. Item

Pharma News

@FiercePharma: The weekend's best-read special report: Top Pharma Companies by 2012 Revenues. Read | Follow @FiercePharma

@EricPFierce: Pfizer gives BlackBerry the raspberry. Piece | Follow @EricPFierce

@CarlyHFierce: Tufts University report: 71% of revenue from the top 10 best-selling meds last year came from #biotech products. Report | Follow @CarlyHFierce

> GlaxoSmithKline CEO: Big Pharma has to be willing to concede in India. News

> Princeton weighs emergency vaccine campaign with Novartis' Bexsero shot. More

> Takeda's new outsider CFO charged with $1B cost-cutting plan. Article

CRO News

> Post-merger PRA makes another buy, grabbing CRI Lifetree. More

> WuXi boosts outlook as Chinese CRO market swells. Story

> Icon rolls out data visualization tech for adaptive trials. News

> Quintiles expands trial monitoring to slash study costs. Article

> Report: Medpace up for $1.2B sale as CRO M&A heats up. Report

> Catalent cuts ribbon on Chinese trial-supply facility. Item

Biotech IT News

> Falling cost of next-gen sequencing to drive informatics boom. News

> Pfizer takes steps to protect itself from BlackBerry's woes. More

> Validic raises cash to turn mHealth app output into data hose. Piece

> Pfizer finally takes control of Twitter account. Item

> EMA warns of possible delay to final trial data transparency policy. Article

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.